Cargando…

Should pediatric idiopathic hypercalciuria be treated with hypocalciuric agents?

BACKGROUND: Hypercalciuria is the most common metabolic risk factor for calcium urolithiasis and is associated with bone loss in adult patients. Reduced bone mineral density (BMD) was already described in idiopathic hypercalciuria (IH) children, but the precise mechanisms of bone loss or inadequate...

Descripción completa

Detalles Bibliográficos
Autores principales: Penido, Maria Goretti Moreira Guimarães, Tavares, Marcelo de Sousa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353600/
https://www.ncbi.nlm.nih.gov/pubmed/34430384
http://dx.doi.org/10.5527/wjn.v10.i4.47
_version_ 1783736436541882368
author Penido, Maria Goretti Moreira Guimarães
Tavares, Marcelo de Sousa
author_facet Penido, Maria Goretti Moreira Guimarães
Tavares, Marcelo de Sousa
author_sort Penido, Maria Goretti Moreira Guimarães
collection PubMed
description BACKGROUND: Hypercalciuria is the most common metabolic risk factor for calcium urolithiasis and is associated with bone loss in adult patients. Reduced bone mineral density (BMD) was already described in idiopathic hypercalciuria (IH) children, but the precise mechanisms of bone loss or inadequate bone mass gain remain unknown. Life-long hypercalciuria might be considered a risk to change bone structure and determine low bone mass throughout life. The peak of bone mass should occur without interferences. A beneficial effect of citrate formulations and thiazides on bone mass in adult and pediatric patients with IH have been shown. AIM: To evaluate whether pharmacological therapy has a beneficial effect on bone mass in children and adolescents with IH. METHODS: This retrospective cohort study evaluated 40 hypercalciuric children non-responsive to lifestyle and diet changes. After a 2-mo run-in period of citrate formulation (Kcitrate) usage, the first bone densitometry (DXA) was ordered. In patients with sustained hypercalciuria, a thiazide diuretic was prescribed. The second DXA was performed after 12 mo. Bone densitometry was performed by DXA at lumbar spine (L2-L4). A 24-h urine (calcium, citrate, creatinine) and blood samples (urea, creatinine, uric acid, calcium, phosphorus, magnesium, chloride, hemoglobin) were obtained. Clinical data included age, gender, weight, height and body mass index. RESULTS: Forty IH children; median age 10.5 year and median time follow-up 6.0 year were evaluated. Nine patients were treated with Kcitrate (G1) and 31 with Kcitrate + thiazide (G2). There were no differences in age, gender, body mass index z-score and biochemical parameters between G1 and G2. There were no increases in total cholesterol, kalemia and magnesemia. Calciuria decreased in both groups after treatment. Lumbar spine BMD z-score increased after thiazide treatment in G2. There was no improvement in G1. CONCLUSION: Results point to a beneficial effect of thiazide on lumbar spine BMD z-score in children with IH. Further studies are necessary to confirm the results of the present study.
format Online
Article
Text
id pubmed-8353600
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-83536002021-08-23 Should pediatric idiopathic hypercalciuria be treated with hypocalciuric agents? Penido, Maria Goretti Moreira Guimarães Tavares, Marcelo de Sousa World J Nephrol Retrospective Cohort Study BACKGROUND: Hypercalciuria is the most common metabolic risk factor for calcium urolithiasis and is associated with bone loss in adult patients. Reduced bone mineral density (BMD) was already described in idiopathic hypercalciuria (IH) children, but the precise mechanisms of bone loss or inadequate bone mass gain remain unknown. Life-long hypercalciuria might be considered a risk to change bone structure and determine low bone mass throughout life. The peak of bone mass should occur without interferences. A beneficial effect of citrate formulations and thiazides on bone mass in adult and pediatric patients with IH have been shown. AIM: To evaluate whether pharmacological therapy has a beneficial effect on bone mass in children and adolescents with IH. METHODS: This retrospective cohort study evaluated 40 hypercalciuric children non-responsive to lifestyle and diet changes. After a 2-mo run-in period of citrate formulation (Kcitrate) usage, the first bone densitometry (DXA) was ordered. In patients with sustained hypercalciuria, a thiazide diuretic was prescribed. The second DXA was performed after 12 mo. Bone densitometry was performed by DXA at lumbar spine (L2-L4). A 24-h urine (calcium, citrate, creatinine) and blood samples (urea, creatinine, uric acid, calcium, phosphorus, magnesium, chloride, hemoglobin) were obtained. Clinical data included age, gender, weight, height and body mass index. RESULTS: Forty IH children; median age 10.5 year and median time follow-up 6.0 year were evaluated. Nine patients were treated with Kcitrate (G1) and 31 with Kcitrate + thiazide (G2). There were no differences in age, gender, body mass index z-score and biochemical parameters between G1 and G2. There were no increases in total cholesterol, kalemia and magnesemia. Calciuria decreased in both groups after treatment. Lumbar spine BMD z-score increased after thiazide treatment in G2. There was no improvement in G1. CONCLUSION: Results point to a beneficial effect of thiazide on lumbar spine BMD z-score in children with IH. Further studies are necessary to confirm the results of the present study. Baishideng Publishing Group Inc 2021-07-25 2021-07-25 /pmc/articles/PMC8353600/ /pubmed/34430384 http://dx.doi.org/10.5527/wjn.v10.i4.47 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Retrospective Cohort Study
Penido, Maria Goretti Moreira Guimarães
Tavares, Marcelo de Sousa
Should pediatric idiopathic hypercalciuria be treated with hypocalciuric agents?
title Should pediatric idiopathic hypercalciuria be treated with hypocalciuric agents?
title_full Should pediatric idiopathic hypercalciuria be treated with hypocalciuric agents?
title_fullStr Should pediatric idiopathic hypercalciuria be treated with hypocalciuric agents?
title_full_unstemmed Should pediatric idiopathic hypercalciuria be treated with hypocalciuric agents?
title_short Should pediatric idiopathic hypercalciuria be treated with hypocalciuric agents?
title_sort should pediatric idiopathic hypercalciuria be treated with hypocalciuric agents?
topic Retrospective Cohort Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353600/
https://www.ncbi.nlm.nih.gov/pubmed/34430384
http://dx.doi.org/10.5527/wjn.v10.i4.47
work_keys_str_mv AT penidomariagorettimoreiraguimaraes shouldpediatricidiopathichypercalciuriabetreatedwithhypocalciuricagents
AT tavaresmarcelodesousa shouldpediatricidiopathichypercalciuriabetreatedwithhypocalciuricagents